Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis

被引：26

作者：

Delmas, PD

机构：

[1] INSERM, Res Unit 403, F-69008 Lyon, France

[2] Univ Lyon 1, F-69365 Lyon, France

来源：

BONE | 2002年 / 30卷 / 01期

关键词：

osteoporosis; fractures; bisphosphonates; estroens; calcitonin; selective estrogen receptor modulators;

D O I：

10.1016/S8756-3282(01)00667-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In postmenopausal osteoporosis, controlled clinical trials with antiresorptive therapies have shown consistent effects on vertebral fracture incidence while their effects on nonvertebral fractures, especially at the hip, have been reported with some agents, but not others. These discrepancies stress the differences in the pathogenesis of vertebral and nonvertebral fractures as discussed below, and the need to further investigate the mechanisms of action of various antiresorptive agents. (C) 2002 by Elsevier Science Inc. All rights reserved.

引用

收藏

页码：14 / 17

页数：4

相关论文

共 28 条

[1] Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats [J].

Ammann, P ;

Rizzoli, R ;

Meyer, JM ;

Bonjour, JP .

OSTEOPOROSIS INTERNATIONAL, 1996, 6 (03) :219-227

[2] THE EFFECTS OF 2-YEAR TREATMENT WITH THE AMINOBISPHOSPHONATE ALENDRONATE ON BONE METABOLISM, BONE HISTOMORPHOMETRY, AND BONE STRENGTH IN OVARIECTOMIZED NONHUMAN-PRIMATES [J].

BALENA, R ;

TOOLAN, BC ;

SHEA, M ;

MARKATOS, A ;

MYERS, ER ;

LEE, SC ;

OPAS, EE ;

SEEDOR, JG ;

KLEIN, H ;

FRANKENFIELD, D ;

QUARTUCCIO, H ;

FIORAVANTI, C ;

CLAIR, J ;

BROWN, E ;

HAYES, WC ;

RODAN, GA .

JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2577-2586

[3] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

[4] Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women [J].

Boivin, GY ;

Chavassieux, PM ;

Santora, AC ;

Yates, J ;

Meunier, PJ .

BONE, 2000, 27 (05) :687-694

[5]

CAULEY JA, 1994, ANN INTERN MED, V122, P9

[6] Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis [J].

Chavassieux, PM ;

Arlot, ME ;

Reda, C ;

Wei, L ;

Yates, AJ ;

Meunier, PJ .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (06) :1475-1480

[7] A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].

Chesnut, CH ;

Silverman, S ;

Andriano, K ;

Genant, H ;

Gimona, A ;

Harris, S ;

Kiel, D ;

LeBoff, M ;

Maricic, M ;

Miller, P ;

Moniz, C ;

Peacock, M ;

Richardson, P ;

Watts, N ;

Baylink, D .

AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276

[8] Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: Does site-specificity exist? [J].

Compston, JE .

BONE, 2000, 27 (06) :765-768

[9] Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].

Cummings, SR ;

Black, DM ;

Thompson, DE ;

Applegate, WB ;

Barrett-Connor, E ;

Musliner, TA ;

Palermo, L ;

Prineas, R ;

Rubin, SM ;

Scott, JC ;

Vogt, T ;

Wallace, R ;

Yates, AJ ;

LaCroix, AZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082

[10] RISK-FACTORS FOR HIP FRACTURE IN WHITE WOMEN [J].

CUMMINGS, SR ;

NEVITT, MC ;

BROWNER, WS ;

STONE, K ;

FOX, KM ;

ENSRUD, KE ;

CAULEY, JC ;

BLACK, D ;

VOGT, TM .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (12) :767-773